Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

HeartWare’s total revenues increase 13% to $73.6 million in second quarter 2015

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $73.6 million for the quarter ended June 30, 2015 compared to $70.1 million for the quarter ended June 30, 2014.

30 Jul 2015

Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

Hospitals that were penalized more frequently in the Hospital-Acquired Condition (HAC) Reduction Program offered advanced services, were major teaching institutions and had better performance on other publicly reported process-of-care and outcome measures, according to a study in the July 28 issue of JAMA, a theme issue on Medicare and Medicaid at 50.

30 Jul 2015

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

When Derrik Neal began having trouble breathing, he initially assumed it was because he was overweight. But after blacking out several times, he learned he had idiopathic pulmonary hypertension. Survival rates at the time he was diagnosed were five years or less - three or less if undetected.

30 Jul 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

One in four people with implanted defibrillators experiences improvements in heart function

A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators -- devices intended to prevent sudden cardiac death from abnormal heart rhythms -- shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.

28 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions at ESC Congress 2015 are set to reveal the latest in cardiovascular disease research across a range of conditions and comorbidities. Hot topics include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease.

23 Jul 2015

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

The National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, director of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.

23 Jul 2015

ICER’s drug assessment program to provide trusted source of information about new drugs

With drug prices for cancer and many other conditions soaring to new highs amid questions about their true value to patients, the Institute for Clinical and Economic Review today launched a program to transform the way new drugs are evaluated and priced in the United States.

22 Jul 2015

HeartWare announces initiation of MVAD System CE Mark international clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced commencement of its MVAD System CE Mark international clinical trial.

20 Jul 2015

New issue of FMCH Journal examines evidence-based population health and patient care

Evidence-Based Approaches to Population Health and Family Practice is the theme of the new issue of Family Medicine and Community Health, an international peer reviewed medical journal with editorial offices in China and the U.S. The Summer 2015 issue includes six original research articles, two educational research articles and two systematic reviews addressing various topics in evidence based population health and patient care.

17 Jul 2015

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.

16 Jul 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.

15 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

University of Liverpool researchers discover common cause of cardiac injury in sepsis patients

Researchers at the University of Liverpool's Institute of Infection and Global Health (IGH) have discovered a common cause of heart damage in patients with sepsis.

10 Jul 2015

FDA approves new heart failure drug

A new drug called Entresto has been approved by the U.S Food and Drug Administration (FDA) for the treatment of heart failure.

9 Jul 2015

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announced today that the US Food and Drug Administration has approved Entresto™ tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

8 Jul 2015

Evidence-based initiative aims to prevent avoidable hospital readmissions

A statewide effort led by key stakeholders in South Carolina successfully organized and implemented an evidence-based initiative aimed at improving the quality of healthcare transitions after hospital discharge to prevent avoidable readmissions.

8 Jul 2015

Sepsis readmissions have significant impact on health care expenditures in California

The Affordable Care Act created several national initiatives aimed at reducing hospital readmission rates for heart attacks, congestive heart failure and other common high-risk conditions. But there is still no national program intended to address sepsis, a potentially life-threatening illness caused by infection.

8 Jul 2015

Heart Failure News and Research

Further Reading

HeartWare’s total revenues increase 13% to $73.6 million in second quarter 2015

Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

One in four people with implanted defibrillators experiences improvements in heart function

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

ICER’s drug assessment program to provide trusted source of information about new drugs

HeartWare announces initiation of MVAD System CE Mark international clinical trial

New issue of FMCH Journal examines evidence-based population health and patient care

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

University of Liverpool researchers discover common cause of cardiac injury in sepsis patients

FDA approves new heart failure drug

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Evidence-based initiative aims to prevent avoidable hospital readmissions

Sepsis readmissions have significant impact on health care expenditures in California

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News